Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up…
All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration's drug shortage database.
The update comes one day after Eli Lilly CEO David Ricks said shortages of Mounjaro and Zepbound would end"very soon." Demand for weight loss and diabetes drugs has trounced supply for months, pushing Eli Lilly and its rival Novo Nordisk to invest billions to ramp up manufacturing.A previous update said some doses of the treatments were still in short supply. Some doses of Mounjaro have been in shortage since as early as 2022, while doses of Zepbound"I think actually today or tomorrow we plan to exit that process," he told the outlet in an interview.
A spokesperson for Eli Lilly did not immediately respond to a request for comment on the FDA's update on Friday.All doses of Novo Nordisk's diabetes injection Ozempic are available in the U.S. as of Friday, according to the FDA's
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage studyThe data adds to mounting evidence that Zepbound and other popular GLP-1 drugs have health benefits beyond promoting weight loss and regulating blood sugar.
Read more »
Weight Loss Drug Zepbound Could Lower Heart Failure Risks, Eli Lilly SaysTy Roush is a New York City-based breaking news reporter who frequently covers Russia’s invasion of Ukraine, the automotive industry and sports money. He joined Forbes in 2022 and has covered Exxon acquiring Pioneer for nearly $60 billion, a mysterious respiratory illness affecting dogs across the U.S.
Read more »
Beyond Novo and Eli Lilly: Watch these biotech and weight loss drug names, fund manager saysYuri Khodjamirian, fund manager at Tema ETFs, says there's a 'valuation opportunity' in biotech stocks at the moment — but also warned of risks.
Read more »
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatmentsQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but come 'too soon,' one analyst said.
Read more »
10 things to watch in the stock market Friday, including tech rotation and Eli Lilly approvalThe S&P 500 and Nasdaq Composite were little unchanged in premarket trading as tech stocks look to stabilize after a rotation from 2024 winners.
Read more »
Amazon, Apple, Eli Lilly: Here's Morgan Stanley's earnings playbookAmazon, Apple, Eli Lilly: Here's Morgan Stanley's earnings playbook
Read more »